NG
NervGen Pharma Corp. Common stock
NGEN · NASDAQ
$2.05 -9.69% (-$0.22)
1M +2.50%
Market Cap $235.8M
P/E Ratio -
Div. Yield -
ROE 1,156.14%
Bulios Fair Price
$1.59
22.4% downside
Trenutna cena
$2.05
Podcenjeno Poštena vrednost Precenjeno
Po podatkih Bulios Fair Price je delnica NGEN trenutno precenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/B 13.63x
P/E N/A
EV/EBITDA N/A
Growth
0 /100
Declining Book val. growth 36.13%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 219.93%
ROE 1,156.14%
ROA 74.79%
Debt
84 /100
Low Debt/Equity 0.00x
Current ratio 1.23x
Int. coverage N/A
Stability
57 /100
Moderate Beta 0.73x
EPS volatility 42.37%
Profitable years 0
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o NGEN
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Adam H. Rogers
Employees
8
Headquarters
West Vancouver
Prihajajoči dogodki
12 NOV.
Earnings
Upcoming earnings report